Meeting
2020 ASCO Virtual Scientific Program
Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.
Authors
Sanne Huijberts
Netherlands Cancer Institute, Amsterdam, Netherlands
Sanne Huijberts , Emilie Van Brummelen , Carla M.L.- Van Herpen , Ingrid M.E. Desar , Frans Opdam , Robin Van Geel , Serena Marchetti , Neeltje Steeghs , Kim Monkhorst , Bas Thijssen , Hilde Rosing , Alwin Huitema , Jos H. Beijnen , Rene Bernards , Jan H. M. Schellens
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT2450656
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3613)
DOI
10.1200/JCO.2020.38.15_suppl.3613
Abstract #
3613
Poster Bd #
343
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.
First Author: Razia Aslam
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2019 ASCO Annual Meeting
Pharmacodynamics of PI3K, MEK, and AKT inhibitors through isoform-specific measurements of MEK, ERK, AKT, and ribosomal protein S6 in needle biopsies.
First Author: William Herrick
First Author: Nuala McCabe